Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Feb 4;115(5):1098-105.
doi: 10.1182/blood-2009-03-207563. Epub 2009 Nov 19.

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Roberto Rodriguez  1 , Ryotaro Nakamura, Joycelynne M Palmer, Pablo Parker, Sepideh Shayani, Auyaporn Nademanee, David Snyder, Vinod Pullarkat, Neil Kogut, Joseph Rosenthal, Eileen Smith, Chatchada Karanes, Margaret O'Donnell, Amrita Y Krishnan, David Senitzer, Stephen J Forman
Affiliations
Clinical Trial

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Roberto Rodriguez et al. Blood. .

Erratum in

  • Blood. 2010 May 27;115(21):4318

Abstract

Combination tacrolimus and sirolimus graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant in patients conditioned with a fractionated total body irradiation-based regimen has shown encouraging results. We studied this prophylaxis combination in 85 patients receiving a matched-sibling transplant conditioned with 3 different regimens:fludarabine-melphalan (n = 46); total body irradiation-etoposide (n = 28), and busulfan-cyclophosphamide (n = 11). The conditioning regimens were completed on day -4. Sirolimus and tacrolimus were started on day -3 to avoid overlap with conditioning therapy. All patients engrafted, with a median time to neutrophil engraftment of 15 days. The cumulative incidence of acute GVHD grades II to IV and III to IV was 43% and 19%, respectively, with no significant difference by conditioning regimen. The 2-year cumulative incidence of chronic GVHD was 46%. With a median follow-up of 26 months, disease-free survival was 58% and overall survival, 66%. The day-100 and 2-year nonrelapse mortality was 4.8% and 10.2%, respectively. The overall incidence of thrombotic microangiopathy was 19%, and it was significantly higher with busulfan/cyclophosphamide (55%, P = .005). Tacrolimus plus sirolimus is an effective combination for acute GVHD prophylaxis and is associated with very low nonrelapse mortality. Thrombotic microangiopathy is a significant complication with this regimen, particularly in patients receiving busulfan/cyclophosphamide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of grade II to IV acute graft-versus-host disease according to conditioning.
Figure 2
Figure 2
Probabilities according to conditioning. Overall survival (A) and nonrelapse mortality (B).
Figure 3
Figure 3
Cumulative incidence with 95% confidence interval. Thrombotic microangiopathy (A) and stratified by conditioning (B).
See this image and copyright information in PMC

Comment in

References

    1. Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Applebaum FR, editors. Thomas' Hematopoitic Cell Transplantation. 3rd ed. Oxford, United Kingdom: Blackwell Publishing; 2004. pp. 635–664.
    1. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc. 2003;35(3):S227–S230. - PubMed
    1. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation. 1999;67(7):1036–1042. - PubMed
    1. Longoria J, Roberts RF, Marboe CC, et al. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. J Thorac Cardiovasc Surg. 1999;117(4):714–718. - PubMed
    1. Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35(3):S193–S200. - PubMed

Publication types

MeSH terms